Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Solid Cancer × Nivolumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 232 Carcinoma, Non-Small-Cell Lung 195 Carcinoma, Renal Cell 122 Neoplasm Metastasis 86 Neoplasms 82 Squamous Cell Carcinoma of Head and Neck 72 Carcinoma, Hepatocellular 70 Colorectal Neoplasms 64 Lung Neoplasms 63 Stomach Neoplasms 47 Pancreatic Neoplasms 45 Head and Neck Neoplasms 38 Carcinoma, Transitional Cell 36 Urinary Bladder Neoplasms 35 Breast Neoplasms 35 Ovarian Neoplasms 32 Hodgkin Disease 32 Triple Negative Breast Neoplasms 29 Brain Neoplasms 28 Small Cell Lung Carcinoma 27 Sarcoma 27 Prostatic Neoplasms 26 Kidney Neoplasms 26 Glioblastoma 26 Recurrence 25 Skin Neoplasms 20 Multiple Myeloma 20 Esophageal Neoplasms 20 Uveal Melanoma 19 Uterine Cervical Neoplasms 18

Interventions

pembrolizumab 2 atezolizumab 2 trastuzumab deruxtecan 1 toripalimab 1 pertuzumab 1 fludarabine 1 durvalumab 1 cabazitaxel 1 XRP6258 1 Trastuzumab 1 S-Adenosylmethionine 1 Ramucirumab 1 Paclitaxel 1 Oxaliplatin 1 Nivolumab 1 Leucovorin 1 Irinotecan 1 Fluorouracil 1 Etoposide 1 Cyclophosphamide 1 Cetuximab 1 Carboplatin 1 Capecitabine 1 Bronchoscopes 1 Bevacizumab 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03721679 2021-02-01

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Oncovir, Inc.

Phase 1/2 Terminated

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡